Fig 1: The impact of polyinosinic:polycytidylic acid [poly (I:C)] treatment on serum TSLP and IL-13 was assessed in a murine model of MC903-induced atopic dermatitis (AD)-like disease (A,B). Western blotting analyses of TLR3, TSLP, and IL-13Ra1 levels (C-F). Densitometric analyses are representative of 3 independent experiments shown in Figure S2. Data are expressed as means ± SD, in (A,B), n=10/group, in (C-F), n=3/group. *, P<0.05, **, P<0.01, ***, P<0.001 vs. 4 days of poly (I:C) injection group.
Fig 2: The impact of polyinosinic:polycytidylic acid [poly (I:C)] treatment on serum IL-4, TSLP, IL-13, and IFN-? was assessed in a murine model of MC903-induced atopic dermatitis (AD)-like disease (A-D). Tissue TSLP and IL-13 levels were additionally measured using enzyme-linked immunosorbent assay (ELISA) kits with normalization to total protein concentrations as quantified by bicinchoninic acid (BCA) assay (E,F). Western blotting analyses of TLR3, TSLP, and IL-13Ra1 levels (G-J). Densitometric analyses are representative of 3 independent experiments shown in Figure S1. Immunohistochemical analyses of TSLP+ and IL-13Ra1+ cells in tissue sections. Scale bar = 100 µm (K). Data are expressed as means ± SD, in (A-F), n=10/group, in (G-J), n=3/group. *, P<0.05, **, P<0.01, ***, P<0.001 vs. MC903 + vehicle treatment group.
Fig 3: Isoliquiritin downregulates the expression of proinflammatory factors in an AD model using NC/Nga mice. Concentrations of IL-4, IgE, TSLP, and IL-6 in serum were determined by ELISA. Results are the mean ± SD; one-way ANOVA; data in bar charts are the mean ± SEM of 6 mice per group (***P<0.001, ****P<0.0001 vs. control group; ####P<0.0001 vs. model group). ISO, isoliquiritin; DEX, dexamethasone; AD, atopic dermatitis; TSLP, thymic stromal lymphopoietin; DNCB, 1-chloro-2,4-dinitrochlorobenzene; SD, standard deviation; ANOVA, Analysis of Variance; SEM, standard error of mean.
Supplier Page from Abcam for Mouse TSLP ELISA Kit